1 Introduction

Non-small cell lung cancer is the leading cause of cancer-related deaths worldwide and is often diagnosed with a poor prognosis (Siegel et al., 2017). Immunotherapy in combination with chemotherapy is recommended to treat patients with stage IV NSCLC without driver alteration (Hanna et al., 2020). Also, there is a potential future perspective of immunotherapy combined with anti-angiogenic agents for treating advanced NSCLC (Liang & Wang, 2019). Some evidence suggests that angiogenesis may be associated with immunosuppression in the tumor microenvironment (TME), thereby enhancing the immune escape of tumor cells (Ohm & Carbone, 2001). The key strategy for targeting TME is to inhibit angiogenesis and stimulate an effective immune response. Anti-angiogenic agents can stimulate the immune system, and immunotherapy might also exert an anti-angiogenic effect. A combination of these agents might produce synergistic effects on treating tumors (Garber, 2014).

Pembrolizumab is a human IgG4 mAb against PD-1. Based on a series of clinical trials, pembrolizumab was approved to treat patients with advanced non-squamous or squamous NSCLC (Hanna et al., 2020). Anlotinib has presented an inhibitory effect on tumor growth and angiogenesis by inhibiting multiple targets such as VEGFR, PDGFR, FGFR, and c-Kit (Lin et al., 2018). Phase III ALTER 0303 showed that anlotinib can significantly prolong the OS and PFS in patients with advanced NSCLC (Han et al., 2018a).

However, currently, there was no report on the effects of combined administration of pembrolizumab and anlotinib on treating patients with advanced NSCLC as yet. Here we report three cases with advanced NSCLC who received a satisfactory response to pembrolizumab combined with anlotinib.
Cases of pembrolizumab combined with anlotinib in NSCLC

Figure 1. A1: PET on Aug 2, 2019, showed a 16 mm*15 mm metastatic nodule in the left upper lobe of the lung, and A2: brain MRI showed a 24 mm*33 mm*28 mm metastatic mass in the right frontal lobe of the brain. PET and brain MRI at March 31, 2020, revealed an outcome of PR with a 15 mm*12 mm nodule in the left upper lobe of the lung (B1) and a 21 mm*14 mm*16 mm mass in the right frontal lobe of the brain (B2).

Figure 2. Chest contrast CT on July 19, 2019, showed a 4.6 cm*3.4 cm*3.2 cm mass in the left upper lobe of the lung and multiple enlarged lymph nodes in the mediastinum and bilateral hilum of the lung (A1,2). Chest CT on Feb 14, 2020, showed an outcome of PR with the left upper mass nearly disappeared (B2) and stable in lymph nodes (B1).
2.2 Case 2

A 73-year-old male complained of cough and bloody sputum. Chest contrast CT and brain MRI on July 19, 2019, showed a 4.6 cm*3.4 cm*3.2 cm mass (SUVmax 12.1) in the left upper lobe of the lung and multiple enlarged lymph nodes in the mediastinum and bilateral hilum of the lung (Figure 2 A1,2). Biopsy by E-BUS from left upper lobe focus and enlarged lymph nodes confirmed the pathology of low moderately differentiated squamous carcinoma with clinical staging of IIIB (cT2N3M0). ECOG PS scores were 0. Biopsy specimens were sent to the pathological department for NGS cancer gene panel (575 genes) test with the results showing clinically significant gene mutation in TP53, PIK3CA, and FGFR1. Histochemistry test for PD-L1 in tumor tissue showed a positive rate of 30%. The patients and his kinsfolk rejected synchronous radical radiotherapy and chemotherapy which we recommended.

With full informed consent, the patients were administered with pembrolizumab (200 mg, q3w) in combination with anlotinib (12 mg, D1-14, q3w) starting from July 25, 2019. Chest CT or PET every 2 months after treatment was applied to assess disease progression. The recent chest CT on Feb 14, 2020, showed an outcome of PR with left upper lobe mass nearly disappeared (Figure 2 B2) and stable in lymph nodes (Figure 2 B1). The ECOG PS was 0 and no bloody sputum was complained. Adverse events of diarrhea and pruritus were observed in this patient but could be controlled by symptomatic treatment. Up to now, the patient was still in PR.

2.3 Case 3

A 50-year-old male complained of cough and dyspnea. A chest X-ray showed a mass in the right upper lung. PET and brain MRI on November 22, 2018, showed a solid mass of 93 mm*82 mm*76 mm in the right upper lobe of the lung and fusion lymph nodes in the right hilum (56 mm*42 mm) of the lung and mediastinum (Figure 3 A1,2). Biopsy by E-BUS from right upper lobe mass and enlarged lymph nodes confirmed the pathology of low moderately differentiated adenocarcinoma with clinical staging of IIIB (cT4N2M0). ECOG PS scores were 1. Biopsy specimens were sent to the pathological department for NGS cancer gene panel (13 genes) test which showed a gene mutation in KRAS G12C. Histochemistry test for PD-L1 in tumor tissue showed a positive rate of 90%. Pemetrexed combined with nedaplatin and bevacizumab was administered for 6 courses starting from December 5, 2018, with an outcome of PR (a cystic-solid mass of 46 mm*40 mm*43 mm in the right upper lobe of the lung and stable fusion lymph nodes on June 15, 2019) (Figure 3 B1). Another four courses of maintenance chemotherapy with pemetrexed combined with bevacizumab were administered with an outcome of SD. Three months after chemotherapy, the patient complained of back pain. PET on October 8, 2019, showed bone metastasis in the fourth thoracic vertebra (SUVmax 11.5) and metastasis in S4 of the liver (B2), and stable of the right upper focus.

With full informed consent, the patients were administered with pembrolizumab (200 mg, q3w) in combination with anlotinib (12 mg, D1-14, q3w) starting from October 17, 2019. PET on December 23, 2019, showed that the metastasis in S4 of the liver disappeared (Figure 3 C2), the SUVmax decreased in the thoracic vertebra metastasis and the main focus and lymph nodes were stable. An SD was obtained. The most recent PET on March 10, 2020, showed a PR with a decrease in size with 3.5 cm*2.5 cm*2.7 cm of fusion lymph nodes in the right hilum (Figure 3 C1). Adverse events of hypertension were observed but could be controlled by united hypotensive drugs.

3 Discussion

This is the first report of patients with advanced NSCLC showing a good response to the combined treatment with pembrolizumab and anlotinib. Anlotinib can inhibit substrate phosphorylation and signal transduction by competing with ATP for binding sites on VEGFR/PDGFR/FGFR/c-kit, therefore exhibiting an effect of inhibiting tumor angiogenesis and tumor growth (Lin et al., 2018). Phase III ALTER 0303 trial evaluated the efficacy and safety of anlotinib in patients with advanced NSCLC. Results showed that anlotinib can significantly prolong the OS (9.6 months vs 6.3 months; HR 0.68; 95% CI 0.54–0.87; P = 0.002) and PFS (5.4 months vs 1.4 months; HR 0.25; 95% CI 0.19–0.31; P < 0.001) compared with placebo treatment (Han et al.2018a). Anlotinib as a third-line treatment provided significant PFS benefits (4.8 vs 1.2 months; hazard ratio (HR) = 0.32; 95% confidence interval (CI), 0.20-0.51; P < 0.0001) to patients with refractory advanced NSCLC compared with placebo (Han et al., 2018b). What’s more, anlotinib played a significant role in the salvage treatment of advanced NSCLC after at least two lines of chemotherapy (Wu et al., 2019).

On the evidence of Keynote 010, for patients with previously treated, PD-L1 positive, advanced NSCLC, pembrolizumab 10 mg/kg significantly improved both OS and PFS compared with docetaxel (Herbst et al., 2016). Keynote 024 found that in patients with previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and without EGFR or ALK alterations, pembrolizumab monotherapy was associated with significantly longer PFS and longer OS over platinum-based chemotherapy (Reck et al., 2016). Furthermore, Keynote 042 suggested that pembrolizumab monotherapy significantly prolonged OS in patients with advanced NSCLC with PD-L1 expression on at least 1% of tumor cells (Mok et al., 2019). Keynote 189 (Gandhi et al., 2018) and Keynote 407 (Paz-Ares et al., 2018) demonstrated that the combination of pembrolizumab and a platinum-based drug standard chemotherapy significantly prolonged PFS and OS over chemotherapy alone in patients with first-line treatment metastatic non-squamous or squamous NSCLC.

A previous study reported a case with advanced metastatic esophageal squamous cell carcinoma who had CR in metastases to the combined treatment with nivolumab and anlotinib.
Cases of pembrolizumab combined with anlotinib in NSCLC

(Tang et al., 2019). According to IMpower150, atezolizumab combined with bevacizumab, paclitaxel, and carboplatin showed a significant PFS benefit in non-squamous NSCLC patients when compared with the combination of bevacizumab, paclitaxel, and carboplatin. However, there was no difference in the response rate between atezolizumab + paclitaxel + carboplatin group and bevacizumab + paclitaxel + carboplatin group. These findings suggest that the anti-angiogenic drug (bevacizumab) has an immunomodulatory effect and can enhance the immune efficacy of atezolizumab (Socinski et al., 2018). Recently, the investigators are focusing on using immunotherapy as a basic therapy in combination with other treatment strategies (such as radiotherapy, chemotherapy, and targeted drugs), which have been thought to increase tumor-related immunogenicity by inducing tumor cell death and new antigen release (Liang & Wang 2019). There was no clinical trial focused on the combined treatment of immunotherapy with anlotinib so far.

Approximately 35% of patients with metastatic NSCLC develop metastases to the brain, which is associated with poor prognosis (Gibson et al., 2018). Pooled analysis of Keynote

Figure 3. PET on November 22, 2018, showed a solid mass of 93 mm*82 mm*76 mm in the right upper lobe of the lung (A1) and fusion lymph nodes in the right hilum (56 mm*42 mm) of the lung and mediastinum (A2); PET on June 15, 2019, showed a cystic-solid mass of 46 mm*40 mm*43 mm in the right upper lobe of the lung and stable fusion lymph nodes (B1); PET on October 8, 2019, showed bone metastasis in the fourth thoracic vertebra (SUVmax 11.5) and metastasis in S4 of the liver (B2); PET on December 23, 2019, showed that the metastasis in S4 of liver disappeared (C2), the SUVmax decreased in the thoracic vertebra metastasis; PET on March 10, 2020, showed a PR with a decrease in size with 3.5 cm*2.5 cm*2.7 cm of fusion lymph nodes in the right hilum (C1).
021,189 and 407 showed that pembrolizumab plus platinum-based chemotherapy improved outcomes over chemotherapy alone in advanced NSCLC patients with brain metastases. Also, post hoc analysis of phase III randomized control trial (ALTER 0303) revealed anlotinib had activity in the brain and played a potential role in tumor control at intracranial sites (Jiang et al., 2020). Pembrolizumab combined with anlotinib benefited the three patients with a manageable safety profile. What’s more, anlotinib improved quality of life compared with placebo in advanced NSCLC patients who had received at least two previous chemotherapies (Si et al., 2018).

In conclusion, the good response in the three patients after treatment with a combination of pembrolizumab combined with anlotinib suggests that the combined treatment of pembrolizumab and anlotinib might be another alternative for treating advanced NSCLC. However, due to limited number of patients enrolled in our study, large cohort clinical study is required to confirm the effect of this combination in the future.

References
Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Dom,e., M., Clingan, P., Hochmair, M. J., Powell, S. E., Cheng, S. Y., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Hui, R., Baron, E. B., Boyer, M., Rubio-Viqueira, B., Novello, S., Kurata, T., Gray, J. E., Vida, J., Wei, Z., Yang, J., Raftopoulos, H., Pietanza, M. C., & Garassino, M. C., & KEYNOTE-189 Investigators. (2018). Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. The New England Journal of Medicine, 378(22), 2078-2092. http://dx.doi.org/10.1056/NE JA MO1810005. PMid:29658856.

Garber, K. (2014). Promising early results for immunotherapy-angiogenesis combination. Journal of the National Cancer Institute, 106(11), dju392. http://dx.doi.org/10.1093/jnci/dju392. PMid:25421345.

Gibson, A. J. W., Li, H., D'Silva, A., Tudor, R. A., Eleighbede, A. A., Otsuka, S. M., Bebb, D. G., & Cheung, W. Y. (2018). Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer. Medical Oncology (Northwood, London, England), 35(9), 117. http://dx.doi.org/10.1007/s12032-018-1182-8. PMid:30073425.

Han, B., Li, K., Wang, Q., Zhang, L., Shi, J., Wang, Z., Cheng, Y., He, J., Shi, Y., Zhao, Y., Yu, H., Zhao, Y., Chen, W., Luo, Y., Wu, L., Wang, X., Pirker, R., Nan, K., Jin, F., Dong, J., Li, B., & Sun, Y. (2018a). Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncology, 4(11), 1569-1575. http://dx.doi.org/10.1001/jama oncol.2018.3039. PMid:30098152.

Han, B., Li, K., Zhao, Y., Li, B., Cheng, Y., Zhou, J., Lu, Y., Shi, Y., Wang, Z., Jiang, L., Luo, Y., Zhang, Y., Huang, C., Li, Q., & Wu, G. (2018b). Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). British Journal of Cancer, 118(5), 654-661. http://dx.doi.org/10.1038/bjc.2017.478. PMid:29438373.

Hanna, N. H., Schneider, B. J., Temin, S., Baker, S. Jr., Brahmer, J., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., Jayiesimi, I., Johnson, D. H., Leigh, N. B., Phillips, T., Riely, G. J., Robinson, A. G., Rosell, R., Schiller, J. H., Singh, N., Spigel, D. R., Stabler, J. O., Tashbar, J., & Masters, G. (2020). Therapy for stage IV Non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update. Journal of Clinical Oncology, 38(14), 1608-1632. http://dx.doi.org/10.1200/JCO.19.03022. PMid:31990617.
Cases of pembrolizumab combined with anlotinib in NSCLC

V., Stara, Z., Su, W.-C., Sugawara, S., Szpak, W., Takahashi, K., Takigawa, N., Tanaka, H., Tan Chun Bing, J., Tang, Q., Tanarow, P., Tejada, H., Tho, L. M., Torii, Y., Trukhyn, D., Turdean, M., Turna, H., Ursol, G., Varela, M., Vallejo, M., Vera, L., Victorino, A.-P., Vlasek, T., Vynnychenko, I., Wang, B., Wang, J., Wang, K., Wu, Y., Yamada, K., Yang, C.-H., Yokoyama, T., Yoshioka, H., Yumuk, F., Zambrano, A., Zarba, J. J., Zarubin, O., Zemaitis, M., Zhang, L., Zhang, L., Zhang, X., Zhao, J., Zhou, C., Zhou, J., Zhou, Q., & Zippelius, A., & KEYNOTE-042 Investigators. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet*, 393(10183), 1819-1830. http://dx.doi.org/10.1016/S0140-6736(18)32409-7. PMid:30955977.

Ohm, J. E., & Carbone, D. P. (2001). VEGF as a mediator of tumor-associated immunodeficiency. *Immunologic Research*, 23(2-3), 263-272. http://dx.doi.org/10.1385/IR:23:2-3:263. PMid:11444391.

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazieres, J., Hermes, B., Cay Şenler, E., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Pipedi, B., & Kowalski, D. M., & KEYNOTE-407 Investigators. (2018). Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *The New England Journal of Medicine*, 379(21), 2040-2051. http://dx.doi.org/10.1056/NEJMoai1810865. PMid:30280635.

Reck, M., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R., & KEYNOTE-024 Investigators. (2016). Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. *The New England Journal of Medicine*, 375(19), 1823-1833. http://dx.doi.org/10.1056/NEJMo1606774. PMid:27718847.

Si, X., Zhang, L., Wang, H., Zhang, X., Wang, M., Han, B., Li, K., Wang, Q., Shi, J., Wang, Z., Cheng, Y., He, J., Shi, Y., Chen, W., Wang, X., Luo, Y., Nan, K., Jin, F., Li, B., Chen, Y., Zhou, J., & Wang, D. (2018). Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. *Lung Cancer (Amsterdam, Netherlands)*, 122, 32-37. http://dx.doi.org/10.1016/j.lungcan.2018.05.013. PMid:30032842.

Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer statistics, 2017. *CA: a Cancer Journal for Clinicians*, 67(1), 7-30. http://dx.doi.org/10.3322/caac.21387. PMid:28055103.

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodriguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., Finley, G., Kelsch, C., Lee, A., Coleman, S., Deng, Y., Shen, Y., Kowanetz, M., Lopez-Chavez, A., Sandler, A., & Reck, M., & IMpower150 Study Group. (2018). Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *The New England Journal of Medicine*, 378(24), 2288-2301. http://dx.doi.org/10.1056/NEJMa1716948. PMid:29863955.

Tang, Y., Ou, Z., Yao, Z., & Qiao, G. (2019). A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma. *Medicine*, 98(40), e17164. http://dx.doi.org/10.1097/MD.0000000000017164. PMid:31577707.

Wu, D., Nie, J., Dai, L., Hu, W., Zhang, J., Chen, X., Ma, X., Tian, G., Han, J., Han, S., Long, J., Wang, Y., Zhang, Z., & Fang, J. (2019). Salvage treatment with anlotinib for advanced non-small cell lung cancer. *Thoracic Cancer*, 10(7), 1590-1596. http://dx.doi.org/10.1111/1759-7714.13120. PMid:31183998.